Plain-English translation of NCT07935031 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage safety study of , a new cell therapy made from human embryonic stem cells. Researchers want to see if this treatment is safe and whether it might help slow or improve symptoms in adults with multiple sclerosis who have had ongoing disease activity despite standard treatments. You would receive a single infusion of the medication into your vein and then be monitored closely for up to 3 years.
Multiple sclerosis can continue to worsen even when people are taking standard disease-modifying medications. This study is exploring whether this new stem cell treatment might offer a different approach to help control the disease and reduce disability.
You likely qualify if…
You likely don't qualify if…
You would have screening visits over 4 weeks, then receive a single infusion of the medication into your vein. After that, you would visit the clinic regularly for 12 months to check for side effects and measure changes in your MS through exams, brain MRI scans, and tests of vision, movement, and thinking. You would then continue in a follow-up program for 24 more months to monitor long-term safety. In total, your participation could last up to 3 years including screening.
AI-generated summary from trial data · Nov 14, 2026 · Not medical advice
China